{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:37:22Z","timestamp":1785490642931,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40262-021-01088-w","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T01:02:34Z","timestamp":1640048554000},"page":"363-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin"],"prefix":"10.1007","volume":"61","author":[{"given":"Kyle C.","family":"Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Van Matre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7415-3999","authenticated-orcid":false,"given":"Tyree H.","family":"Kiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"1088_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:940\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR2","unstructured":"Dalbavancin [package insert]. Chicago, IL: Durata Therapeutics."},{"key":"1088_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/cid\/civ982","volume":"62","author":"MW Dunne","year":"2016","unstructured":"Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62:545\u201351.","journal-title":"Clin Infect Dis"},{"key":"1088_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jgar.2019.02.007","volume":"17","author":"U Rappo","year":"2019","unstructured":"Rappo U, Gonzalez PL, Puttagunta S, Akinapelli K, Keyloun K, Gillard P, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019;17:60\u20135.","journal-title":"J Glob Antimicrob Resist."},{"key":"1088_CR5","doi-asserted-by":"crossref","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2018;6(1):ofy3319. https:\/\/academic.oup.com\/ofid\/article\/6\/1\/ofy331\/5235615. Accessed 3 Jun 2019.","DOI":"10.1093\/ofid\/ofy331"},{"key":"1088_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","volume":"18","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin D\u00e1vila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18:30.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1088_CR7","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","volume":"74","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019;74:2405\u201316.","journal-title":"J Antimicrob Chemother"},{"key":"1088_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/phar.2389","volume":"40","author":"M Krsak","year":"2020","unstructured":"Krsak M, Morrisette T, Miller M, Molina K, Huang M, Damioli L, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review. Pharmacotherapy J Hum Pharmacol Drug Therapy. 2020;40:469\u201378.","journal-title":"Pharmacotherapy J Hum Pharmacol Drug Therapy."},{"key":"1088_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67:795\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1088_CR10","first-page":"229","volume":"3","author":"M Steiert","year":"2002","unstructured":"Steiert M, Schmitz F-J. Dalbavancin Biosearch Italia\/Versicor. Curr Opin Investig Drugs. 2002;3(2):229\u201333.","journal-title":"Curr Opin Investig Drugs"},{"key":"1088_CR11","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2174\/0929867013371716","volume":"8","author":"A Malabarba","year":"2001","unstructured":"Malabarba A, Ciabatti R. Glycopeptide derivatives. CMC. 2001;8:1759\u201373.","journal-title":"CMC."},{"key":"1088_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jac\/44.2.179","volume":"44","author":"G Candiani","year":"1999","unstructured":"Candiani G, Abbondi M, Borgonovi M, Roman\u00f2 G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999;44:179\u201392.","journal-title":"J Antimicrob Chemother"},{"key":"1088_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1179\/joc.2001.13.3.244","volume":"13","author":"RN Jones","year":"2001","unstructured":"Jones RN, Biedenbach DJ, Johnson DM, Pfaller MA. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother. 2001;13:244\u201354.","journal-title":"J Chemother"},{"key":"1088_CR14","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1093\/jac\/dky235","volume":"73","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316. J Antimicrob Chemother. 2018;73:2748\u201356.","journal-title":"J Antimicrob Chemother"},{"key":"1088_CR15","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1128\/AAC.47.6.1968-1971.2003","volume":"47","author":"EJC Goldstein","year":"2003","unstructured":"Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT. In vitro activities of Dalbavancin and nine comparator agents against anaerobic Gram-Positive species and Corynebacteria. Antimicrob Agents Chemother. 2003;47:1968\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","volume":"36","author":"D Knafl","year":"2017","unstructured":"Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36:677\u201380.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"1088_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/1120009X.2021.1911518","volume":"33","author":"V Silva","year":"2021","unstructured":"Silva V, Miranda C, Bezerra M, Ant\u00e3o HS, Guimar\u00e3es J, Prada J, et al. Anti-biofilm activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) isolated from human bone infection. J Chemother. 2021;33(7):469\u201375.","journal-title":"J Chemother"},{"key":"1088_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1345\/aph.1G158","volume":"40","author":"S-W Lin","year":"2006","unstructured":"Lin S-W, Carver PL, DePestel DD. Dalbavancin: a new option for the treatment of Gram-positive infections. Ann Pharmacother. 2006;40:449\u201360.","journal-title":"Ann Pharmacother"},{"key":"1088_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/cr030103a","volume":"105","author":"D Kahne","year":"2005","unstructured":"Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev. 2005;105:425\u201348.","journal-title":"Chem Rev"},{"issue":"Suppl 2","key":"1088_CR20","doi-asserted-by":"publisher","first-page":"ii31","DOI":"10.1093\/jac\/dki006","volume":"55","author":"M Cavaleri","year":"2005","unstructured":"Cavaleri M, Riva S, Valagussa A, Guanci M, Colombo L, Dowell J, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005;55(Suppl 2):ii31-35.","journal-title":"J Antimicrob Chemother"},{"key":"1088_CR21","unstructured":"White RJ, Brown GL, Cavelero M, Romano G. V-glycopeptide: Phase 1 single and multiple-dose placebo controlled intravenous safety, pharmacokinetic and pharmacodynamic study in healthy subjects. In: 40th ICAAC; 17\u201320 Sep 2000: Toronto, ON [abstract no. 2196]."},{"key":"1088_CR22","unstructured":"Cavaleri M, Cooper A, Nutley MA, Stogniew M. Protein Binding of Dalbavancin Using Isothermal Titration Microcalorimetry 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 27\u201330 Sep 2002: San Diego, CA [abstract no. 1385]."},{"issue":"2","key":"1088_CR23","first-page":"P21","volume":"71","author":"MK Jordan","year":"2002","unstructured":"Jordan MK, Forrest A, Leighton A, et al. A novel use of optimal sampling theory (OST) during drug development [abstract MPI-65]. Clin Pharmacol Ther. 2002;71(2):P21.","journal-title":"Clin Pharmacol Ther"},{"key":"1088_CR24","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/379015","volume":"37","author":"E Seltzer","year":"2003","unstructured":"Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298\u2013303.","journal-title":"Clin Infect Dis"},{"key":"1088_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpdd.695","volume":"9","author":"TJ Carrothers","year":"2020","unstructured":"Carrothers TJ, Chittenden JT, Critchley I. Dalbavancin population pharmacokinetic modeling and target attainment analysis. Clin Pharmacol Drug Dev. 2020;9:21\u201331.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1088_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1128\/AAC.01264-06","volume":"51","author":"D Andes","year":"2007","unstructured":"Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51:1633\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR27","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.1128\/AAC.01717-15","volume":"59","author":"A Lepak","year":"2015","unstructured":"Lepak A, Marchillo K, VanHecker J, Andes D. Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target. Antimicrob Agents Chemother. 2015;59:7833\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0091270008330162","volume":"49","author":"T Marbury","year":"2009","unstructured":"Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49:465\u201376.","journal-title":"J Clin Pharmacol"},{"key":"1088_CR29","unstructured":"Dalbavancin [package insert]. Madison, NJ: Allergan."},{"key":"1088_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40261-015-0340-4","volume":"35","author":"PJ Scoble","year":"2015","unstructured":"Scoble PJ, Owens RC, Puttagunta S, Yen M, Dunne MW. Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of Dalbavancin in healthy Japanese subjects. Clin Drug Investig. 2015;35:785\u201393.","journal-title":"Clin Drug Investig"},{"key":"1088_CR31","doi-asserted-by":"publisher","first-page":"ii25","DOI":"10.1093\/jac\/dki008","volume":"55","author":"MB Dorr","year":"2005","unstructured":"Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrobial Chemotherapy. 2005;55:ii25-30.","journal-title":"J Antimicrobial Chemotherapy."},{"key":"1088_CR32","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/INF.0000000000000646","volume":"34","author":"JS Bradley","year":"2015","unstructured":"Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE. Pharmacokinetics, safety and tolerability of single dose Dalbavancin in children 12\u201317 years of age. Pediatr Infect Dis J. 2015;34:748\u201352.","journal-title":"Pediatr Infect Dis J"},{"key":"1088_CR33","unstructured":"Allergan. A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections. ClinicalTrials.gov; Jan 2021. ClinicalTrials.gov identifier: NCT02814916. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02814916."},{"key":"1088_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/FTD.0000000000000729","volume":"42","author":"A Corona","year":"2020","unstructured":"Corona A, Agarossi A, Veronese A, Cattaneo D, D\u2019Avolio A. Therapeutic drug monitoring of Dalbavancin treatment in severe necrotizing fasciitis in 3 critically ill patients: a grand round. Ther Drug Monit. 2020;42:165\u20138.","journal-title":"Ther Drug Monit"},{"key":"1088_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/jac\/dkm263","volume":"60","author":"DP Nicolau","year":"2007","unstructured":"Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60:681\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"1088_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","volume":"75","author":"RN Jones","year":"2013","unstructured":"Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75:304\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1088_CR37","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1128\/AAC.00020-07","volume":"51","author":"EG Solon","year":"2007","unstructured":"Solon EG, Dowell JA, Lee J, King SP, Damle BD. Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits. Antimicrob Agents Chemother. 2007;51:3008\u201310.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1088_CR38","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C. Extended-duration dosing and distribution of Dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1088_CR39","doi-asserted-by":"publisher","first-page":"E01024","DOI":"10.1128\/AAC.01024-19","volume":"63","author":"U Rappo","year":"2019","unstructured":"Rappo U, Dunne MW, Puttagunta S, Baldassarre JS, Su S, Desai-Krieger D, et al. Epithelial lining fluid and plasma concentrations of Dalbavancin in healthy adults after a single 1,500-milligram infusion. Antimicrob Agents Chemother. 2019;63(11):E01024-E1119.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR40","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1128\/AAC.00116-16","volume":"60","author":"RN Jones","year":"2016","unstructured":"Jones RN, Schuchert JE, Mendes RE. Dalbavancin activity when tested against Streptococcus pneumoniae isolated in medical centers on six continents (2011 to 2014). Antimicrob Agents Chemother. 2016;60:3419\u201325.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1088_CR41","doi-asserted-by":"crossref","first-page":"e02089","DOI":"10.1128\/AAC.02089-19","volume":"64","author":"ET Van Matre","year":"2020","unstructured":"Van Matre ET, Teitelbaum I, Kiser TH. Intravenous and intraperitoneal pharmacokinetics of Dalbavancin in peritoneal dialysis patients. Antimicrob Agents Chemother. 2020;64(5):e02089-e2119.","journal-title":"Antimicrob Agents Chemother"},{"key":"1088_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-0040-1715720","volume":"14","author":"KCM Campbell","year":"2003","unstructured":"Campbell KCM, Kelly E, Targovnik N, Hughes L, Van Saders C, Gottlieb AB, et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol. 2003;14:157\u201368 (quiz 170\u20131).","journal-title":"J Am Acad Audiol"},{"key":"1088_CR43","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/jac\/dkl281","volume":"58","author":"CE Nord","year":"2006","unstructured":"Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother. 2006;58:627\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"1088_CR44","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","volume":"24","author":"BJ Werth","year":"2018","unstructured":"Werth BJ, Jain R, Hahn A, Cummings L, Weaver T, Waalkes A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018;24:429.e1-429.e5.","journal-title":"Clin Microbiol Infect"},{"key":"1088_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","volume":"7","author":"M Kussmann","year":"2018","unstructured":"Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D, et al. Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect. 2018;7:202.","journal-title":"Emerg Microbes Infect."},{"key":"1088_CR46","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","volume":"27","author":"BJ Werth","year":"2021","unstructured":"Werth BJ, Ashford NK, Penewit K, Waalkes A, Holmes EA, Ross DH, et al. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2021;27:910.e1-e8.","journal-title":"Clin Microbiol Infect"},{"key":"1088_CR47","unstructured":"University of Colorado, Denver. Evaluation of Intravenous Dalbavancin for Treatment of Peritonitis in Peritoneal Dialysis Patients. ClinicalTrials.gov; 2020 Nov. ClinicalTrials.gov identifier: NCT04624451. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04624451."},{"key":"1088_CR48","unstructured":"University of Colorado, Denver. Preliminary Evaluation of Dalbavancin\u2019s Efficacy in People Who Use Drugs With Severe Gram-positive Infections. ClinicalTrials.gov; 2021 May. ClinicalTrials.gov identifier NCT04847921. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04847921."},{"issue":"11","key":"1088_CR49","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0091270005280378","volume":"45","author":"M Buckwalter","year":"2005","unstructured":"Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005;45(11):1279\u201387.","journal-title":"J Clin Pharmacol."},{"issue":"7","key":"1088_CR50","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/INF.0000000000001538","volume":"36","author":"D Gonzalez","year":"2017","unstructured":"Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, et al. Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age. Pediatr Infect Dis J. 2017;36(7):645\u201353.","journal-title":"Pediatr Infect Dis J."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01088-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01088-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01088-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T07:52:38Z","timestamp":1676101958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01088-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01088-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"2 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tyree H. Kiser reports previous investigator-initiated dalbavancin research funding paid to his institution from Allergan Pharmaceuticals. Matthew A. Miller reports participation in the speaker\u2019s bureau for Allergan Pharmaceuticals. Kyle C. Molina, Scott W. Mueller, Edward Van Matre, and Martin Krsak have no disclosures to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}